About us

ABOUT US

XING Technologies is an Australian-based biotechnology company specialising in transformative diagnosis and monitoring technologies for cancer and disease.

The company’s proprietary nanotechnologies are transforming the future practice of medicine and enabling personalised healthcare. XING’s service and product lines currently span from cancer care to rapid nucleic acid extraction, protein detection diagnostics and nanoparticle capture agents to identify and prevent the spread of infectious diseases.

“The dedicated team of scientists is solely focused on improving the quality of life of patients affected by cancer" –

Paul Mainwaring – Co-Founder, CEO & Chairman

Dr Paul Mainwaring

Co-Founder & Executive Chairman & CEO

Yadveer S. Grewal, PhD

Product Manager

Dr Lynn Fink

Technical Director

John Nguyen 

Quality & Regulatory Affairs Manager

Scroll to Top

Dr Paul Mainwaring

Co-Founder & Executive Chairman

Paul worked as a medical oncologist for 25 years, with an emphasis on basic, clinical and translational research applying new technologies to deliver the best available personalised care to patients and their carers. He published extensively in the world’s leading cancer journals including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology amongst others.

After Paul’s initial Medical Oncology training in Sydney at Royal Prince Alfred and Royal North Shore hospitals he moved to the Royal Marsden in London – Europe’s largest cancer hospital. Paul completed his MD in cell death at the Institute of Cancer Research and was appointed as a consultant at Guy’s, King’s and St Thomas’ NHS Trusts in 1999.

In 2002, Paul returned to Australia as Director of Medical Oncology, Mater Adult Hospital and in 2008 Paul transferred across into private practice in Queensland continuing his translational & clinical research. As part of this work he came across the disruptive nanotechnologies being developed in Queensland that could transform patient care.

In 2019, Paul transitioned across from working as a medical oncologist to XING to assist the brilliant team of researchers in bringing the XING vision to patients.

Yadveer S. Grewal, PhD

Product Manager

Yadveer leads the Protein Chemistry development team and with the team, drives the advancement of the XavTrap® platform and serves as the Product Manager. Prior to joining XING, Yadveer co-invented the XavTrap® technology during his PhD in Nanobiotechnology at The University of Queensland. Yadveer has been awarded $1.25M USD in grant funding from the US National Institutes of Health RADx program to commercialise the XavTrap® platform.

Dr Lynn Fink

Technical Director

Following a successful academic career in computational cancer genomics research, Lynn made the leap to industry in order to focus on using novel and disruptive technologies to address unmet clinical needs. 

After serving as a Director of Research for the world’s largest genomics company, she joined XING Pathology team as Laboratory Director of NATA accredited ISO15189 human pathology lab and also serves as Technical Director for XING Technologies in order to help advance point-of-care medical device technologies.

Lynn has been involved in large, international research consortia including the International Cancer Genome Consortium (ICGC), which has resulted in a major resource of almost 3,000 whole cancer genomes, underpinning most cancer genome research projects. 

To date, Lynn has over 70 publications in molecular biology and bioinformatics many of which are in high-impact journals such as Nature, Nature Methods, Nature Genetics, Nature Communications, PNAS, PLoS Genetics, Genome Research, and Genome Biology.

John DT Nguyen

Quality & Regulatory Affairs Manager

Experienced Quality Systems, Regulatory Affairs & Product Development Professional with extensive experience working with startup to global renowned companies regulated by TGA, FDA and EU guidelines and standards. Excellent technical knowledge within the medtech/healthcare industry that can be applied to further enhance the reputation of the company and play an important role in maintaining the highest quality standard in the company whilst maintaining regulatory compliance.